Therapy

Many of us over the course of our clinical practice have cared for patients with pulmonary arterial hypertension (PAH) and have hoped for better therapies.

Epistaxis, dizziness, and telangiectasia were more common in patients receiving sotatercept compared to placebo. Furthermore, sotatercept reduced the risk of death and non-fatal clinical deterioration by 84% compared to placebo (HR: 0.16 [95% CI: 0.08 to 0.35]). Patients had to be on background therapy for at least 90 days before enrollment and had to have a pulmonary vascular resistance of 5 Wood units or more. Many of us over the course of our clinical practice have cared for patients with pulmonary arterial hypertension (PAH) and have hoped for better therapies in this challenging patient population. STELLAR is a multicenter, double-blind, phase 3 trial, which randomized patients with pulmonary arterial hypertension (PAH) (WHO functional Class II or III) on background PAH therapy to sotatercept or placebo. For randomization, patients were stratified by their WHO class (II or III) and degree of background PAH therapy (monotherapy, double therapy, or triple therapy).

Heading into 2020 — the first year of the Patient-Driven Groupings Model (PDGM) — many believed there would be an inevitable disruption to home health.

More clarity should come in the next few months, two of the largest therapy associations in the U.S. SPONSORED BY: Innovative talent drives the aging industry forward. More than three years later, it’s still unclear exactly how PDGM has impacted therapy, and how the industry can differentiate PDGM’s impact versus the pandemic’s.

When added to standard treatment, mindfulness-based cognitive therapy (MBCT) may have favourable effects for patients with bipolar disorder and modera...

Moreover, 51 (71 percent) participants reported still practicing formal mindfulness exercises regularly at 3 months (mean frequency per week 3.5, mean minutes per week 21.0). They were randomly assigned to receive treatment as usual (TAU) alone (n=72) or in combination with MBCT (n=72). At 6 months, the number of participants who still practiced MBCT decreased to 37 (51 percent) participants (mean frequency per week 2.7, mean minutes per week 15.2), and this remained until 15 months. In the MBCT plus TAU group, participants who attended not more than four MBCT sessions (n=18) did not differ from those who completed MBCT. When added to standard treatment, mindfulness-based cognitive therapy (MBCT) may have favourable effects for patients with The study involved 144 participants (mean age was 46.6 years, 60 percent women) with bipolar disorder type I and II.

There is a promising treatment on the horizon for patients with dystrophic epidermolysis bullosa (DEB), according to Isin Sinem Bagci, MD, a presenter in ...

Presented at the 2023 Annual Meeting of the American Academy of Dermatology. Complete wound healing occurred in 67% of the wounds exposed to B-VEC, in comparison to 22% of those exposed to placebo. Of the 45 reported adverse events, 58% were considered mild and 48% were considered moderate. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. Based on the data, Krystal Biotech announced a home dosing extension study in April 2022, she said. Over a 26-week period, 2 wounds on each patient that were of similar size, anatomical region, and appearance were randomized to receive application of B-VEC or placebo once per week until the wound closed (treatment was resumed if the wound reopened). Gene therapy of the skin and its integration into clinical practice. “It was decreasing his quality of life; it was a major problem,” she told attendees. After treatment, she said the patient reportedly could shower as well as lay on their back without significant pain. Based on this data, Bagci expected “a redosable/in vivo/topical gene therapy [would be] emerging this year in the genetic disease field,” she told attendees. Similarly, she noted 71% of the wounds were deemed completely healed at 3 months for those exposed to B-VEC as opposed to 20% of those wounds exposed to placebo. DEB is caused by mutations in COL7A1, a gene involved in assembling type 7 collagen and plays a crucial role in stabilizing the skin, Bagci explained.